Tirzepatide
Dual Agonist Peptide
Also referred to as Mounjaro, Zepbound, LY3298176.
Tirzepatide is a synthetic dual agonist peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, identified in the literature under development code LY3298176. It was among the first compounds in its class to combine these two incretin targets in a single molecule.
The published evidence base is comparatively strong for a research peptide: multiple phase 3 randomized controlled trials address glycemic control in type 2 diabetes and weight reduction in obesity, with research spanning 2021 through 2025. Head-to-head comparison data against semaglutide has been generated, though long-term cardiovascular outcomes and durability of effect after discontinuation remain open questions.
Published on Tirzepatide
- comparisonTirzepatide Peptide vs Cagrilintide: What Does the Research Say?Tirzepatide peptide is a synthetic, fatty-acid-modified dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, designed for once-weekly subcutaneous administration.
- Research OverviewTirzepatide Peptide: How Does It Work? Mechanism of Action ExplainedTirzepatide is a synthetic, fatty acid–modified peptide designed to act simultaneously on two distinct gut hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.